Advertisement


Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases

2024 ASCO Annual Meeting

Advertisement

Minesh P. Mehta, MD, of Miami Cancer Institute, part of Baptist Health South Florida, discusses results from the METIS (EF-25) trial evaluating the efficacy and safety of tumor treating fields therapy following stereotactic radiosurgery in patients with mutation-negative non–small cell lung cancer (NSCLC) and brain metastases. Tumor treating fields therapy prolongs time to intracranial disease progression and may postpone whole-brain radiation therapy without declines in quality of life and cognition (Abstract 2008).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
It's a pleasure to be here today to talk about the EF-25 METIS trial. This was a clinical trial evaluating the use of tumor treating fields therapy in patients with non-small cell lung cancer with brain metastasis that are mutation negative. Just under 300 patients, 298 to be precise, were randomized to receiving stereotactic radiosurgery, which is the standard of care for these patients, but is characterized with high rate of intracranial relapse. Following stereotactic radiosurgery, patients received best supportive care in the control arm or best supportive care plus tumor treating fields therapy. The primary endpoint of the trial was to determine if the rate of intracranial progression and the time to intracranial progression could be altered with the use of tumor treating fields therapy. And in fact, the key top line result of the trial was indeed precisely that. The time to intracranial progression was significantly lengthened in favor of tumor treating fields by 10.6 months, and therefore the median time to progression was 10.3 months in the control arm and 21.9 months in the experimental or tumor treating fields arm. This was a significant prolongation. In association with this prolongation of tying to intracranial progression, quality of life metrics also favored tumor treating fields therapy. There was a greater sustenance of quality of life and a greater durability of quality of life in patients receiving tumor treating fields therapy. Overall, the safety was exceptionally well tolerated. Only 2.3% of patients experienced grade three or higher toxicities that were device related. This is a very well tolerated therapy and prolongs time to intracranial progression, which is the top line result. Other secondary endpoints are currently being evaluated and we look forward to reporting those out shortly.

Related Videos

Lymphoma

Joshua D. Brody, MD, on Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

Joshua D. Brody, MD, of the Icahn School of Medicine at Mount Sinai, discusses results from the EPCORE NHL-2 study, which was designed to evaluate the safety and efficacy of epcoritamab-bysp plus rituximab and lenalidomide in the first-line setting for patients with follicular lymphoma and to assess epcoritamab as maintenance therapy in this population (Abstract 7014).

Gynecologic Cancers

Don S. Dizon, MD, on Ovarian and Other Extrarenal Clear Cell Carcinomas: Update on Nivolumab and Ipilimumab

Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).

Prostate Cancer
Genomics/Genetics

Alicia Morgans, MD, MPH, and Susan Halabi, PhD, on Prostate Cancer: New Findings on Classifying Patients Into Risk Groups

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).

Lymphoma

Peter Riedell, MD, on DLBCL: Expert Commentary on Data From the ECHELON-3 Study

Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).

Lung Cancer

Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent

Tomasz Jankowski, MD, PhD, of Poland’s Medical University in Lublin, discusses a phase II study of THIO, a telomere-targeting agent followed by cemiplimab-rwlc for a difficult-to-treat population of patients with advanced non–small cell lung cancer (Abstract 8601).

Advertisement

Advertisement




Advertisement